Phaeochromocytoma in children

Archives of Disease in Childhood

Volumn 93, Issue 10, 2008, Pages 899-904

  Armstrong, R ^a   Sridhar, M ^a   Greenhalgh, K L ^a   Howell, L ^a   Jones, C ^a   Landes, C ^a   McPartland, J L ^a   Moores, C ^a   Losty, P D ^a   Didi, M ^a  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SUCCINATE DEHYDROGENASE;

FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; RARE DISEASE; REVIEW; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; CHILD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PHEOCHROMOCYTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 53549115352     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2008.139121     Document Type: Review

References (62)

1. Neumann HPH, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-66.
2. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann NY Acad Sci 2006;1073:30- 7.
3. Delellis RA, Lloyd RV, Heitz PU, et al (eds). Tumours of endocrine organs: pathology and genetics. Geneva: World Health Organization, 2004.
4. Pickard JL, Ross G, Silver D. Coexisting extraadrenal pheochromocytoma and renal artery stenosis: A case report and review of the pathophysiology. J Pediatr Surg 1995;30:1613-15.
5. British Society of Paediatric Endocrinology & Diabetes. Paediatric Endocrine Tumours. A Multidisciplinary Consensus Statement of Best Practice from a Working Group Convened Under the Auspices of the BSPED and UKCCSG, 2005. http://www. bsped.org.uk/professional/guidelines/index.htm (accessed 27 Jun 2008).
6. Perel Y, Schlumberger M, Alos N, et al. Pheochromocytoma and paraganglioma in children: a report of 24 cases of the French Society of Pediatric Oncology. Pediatr Hematol Oncol 1997;14:413-22.
7. Beltsevich DG. Kuznetsov NS, Kazaryan AM, et al. Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg 2004;28:592-6.
8. Kaufman BH, Telander RL, van Heerden JA, et al. Pheochromocytoma in the pediatric age group: current status. J Pediatr Surg 1983;18:879-84.
9. Cifti AO, Tanyel C, Senacak ME, et al. Pheochromocytoma in children. J Pediatr Surg 2001;36:447-52.
10. Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care centre. Pediatrics 2006;118:1109-17.
11. McNeil AR, Blok BH, Koelmeyer TD, et al. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med 2000;30:648-52.
12. Bravo EL, Tarazi RC, Gifford RW, et al. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 1979;301:682-6.
13. Young WF Jr. Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 1997;28:801-27.
14. Eisenhofer G, Keiser K, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O- methyltransferase within tumours. J Clin Endocrinol Metab 1998;83:2175-85.
15. Eisenhofer G, Goldstein GS, Kopin IJ, et al. Pheochromocytoma: rediscovery as a catecholamine-metabolising tumours. Endocr Pathol 2003;14:193-212.
16. Lenders JWM, Keiser HR, Goldstein OS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995;123:101-9.
17. Sawka AM, Ravinder JR. Singh J, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. Clin Endocrinol Metab 2003;88:553-8.
18. Lagerstedt SA, O'Kane DJ, Singh RJ. Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem 2004;50:603-11.
19. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium, October 2005. Nat Clin Pract Endocrinol Metab 2007;3:92-102.
20. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001;86:5210-16.
21. Dahnert W. Radiology review manual. 5th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2003;935-6.
22. Esfandiari NH, Shulkin BL, Bui C, et al. Multimodality imaging of malignant pheochromocytoma. Clin Nucl Med 2006;31:822- 5.
23. Timmers HG, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated phaeochromocytoma and paraganglioma. J Clin Orthod 2007;25:2262-9.
24. Rozovsky K, Koplewitz BZ, Krausz Y, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085-90.
25. Geffand MJ, Lemen LC. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager. Semin Nucl Med 2007;37:391-8.
26. Mannelli M, Ercolino T, Giache V, et al. Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J Med Genet 2007,44:586-7.
27. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to Eg1N3 prolyl hydrolase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005;8:155-67.
28. Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up. Surg Oncol Clin N Am 1998;7:765-89.
29. Groshonq T. Hypertensive crisis in children. Pediatr Ann 1996;25:368-71, 375-6.
30. Brouwers FM. Eisenhofer G, Lenders, JWM. Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. Endocrinol Metab Clin N Am 2006:35:699-724.
31. Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol 1999;17:35-9.
32. Pacak K. Linehan MW, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:315-29.
33. Kocak S, Aydintug S, Canakci N. Alpha blockade in preoperative preparation of patients with pheochromocytomas. Int Surg 2002;87:191-4.
34. Pullerits J, Ein S, Balfe JW. Anaesthesia for phaeochromocytoma. Can J Anaesth 1988:35:526-34.
35. Perry RR, Keiser HR, Norton JA, et al. Surgical management of pheochromoctyoma with the use of metyrosine. Ann Surg 1990;212:621-8.
36. Lebuffe G, Dosseh ED. Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005;60:439-44.
37. Shops DG. Jiang NS. Klee GG. Recent developments in the diagnosis and treatment of pheochromocytoma. Mayo Clin Proc 1990;65:88.
38. Skinner MA, Safford SD. Endocrine disorders and tumours. In: Ashcraft KW, Holcomb III GW, Murphy JP, eds. Pediatric surgery. Philadelphia: Elsevier Saunders, 2005.
39. Fusai G, Steinberg R, Prachalias A, et al. Ex vivo surgery for extraadrenal pheochromocytoma. Pediatr Surg Int 2006;22:282-5.
40. Caty MG, Coran AG. Geagen M, et al. Current diagnosis and treatment of pheochromocytoma in children. Arch Surg 1990;125:978- 81.
41. Ludwig AD, Feig Dl. Brandt ML, et al. Recent advances in the diagnosis and treatment of pheochromocytoma in children. Am J Surg 2007;194:792-6.
42. Gagner M, Lacroix A, Bolte E. laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. N Engl J Med 1992:327:1033.
43. Kravarusic D, Pinto-Rojas A, Al-Assiri A, et al. Laparoscopic resection of extraadrenal pheochromocytoma: case report and review of the literature in pediatric patients. J Pediatr Surg 2007;42:1780-4.
44. Koch CA, Maura D, Walther MM, et al. Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 2002;13:17-27.
45. Eisenhofer G, Huynh TT, Pacak K, et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-ündau syndrome. Endocr Relat Cancer 200411:897- 911.
46. Linnoila Rl, Keiser HR. Steinberg SM, et al. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 1990;21:1168-80.
47. Tischler AS, Kimura N, McNicol AM. Pathology of pheochromocytoma and extraadrenal paraganglioma. Ann NY Acad Sci 2006;1073:557-70.
48. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002;26:551-66.
49. Kimura N, Watanabe T, Noshiro T, et al. Histological grading of adrenal and extraadrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 2005;16:23-32.
50. Association of Directors of Anatomic and Surgical Pathology. Checklist for adrenal cortical carcinoma and phaeochromocytoma, November 2003. http://www adasp.org (accessed 27 Jun 2008).
51. Royal College of Pathologists. Dataset for histopathology reporting in adrenal cortical carcinoma and malignant phaeochromocytoma/ paraganglioma, amended March 2006. http://www.rcpath.org (accessed 27 Jun 2008).
52. Salmenkivi K, Hagkind C, Arola J. et al. Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol 2001;25:1419-23.
53. Salmeinkvi K, Haglund C, Ristimäki A. et al. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:5615-19.
54. Salmenkivi K, Heikkilä P. Liu J, et al. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 2003;111:458-64.
55. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005;23:8812-18.
56. Neumann HP, Pawlu C. Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 943-51.
57. Buscombe J, Cwikla J. Caplin M, et al. Long-term efficacy of low activity meta-[137]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 2005;26:969-76.
58. Duet M, Guichard J, Rizzo N, et al. Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas? Laryngoscope 2005;115:1381-4.
59. Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007;92:1217-25.
60. Mukherjee JJ, Kaftsas GA. Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)l-metaiodobenzylguanidine ((131)I-MIBG}. Clin Endocrinol (Oxf) 2001;55:47-60.
61. Johnston LB, Chew SL. Trainer PJ, et al. Screening children at risk of developing inherited endocrine neoplasia syndromes. Clin Endocrinol 2000;52:127-36.
62. Ferner R, Huson SM. Thomas N. et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 (NF1). J Med Genet published online 14 Nov 2006; doi:10.1136/jmg.2006.045906.